MD4316C1 - Utilizarea propionatului de 3-(2, 2, 2-trimetilhidraziniu) dihidrat pentru tratamentul gastropatiilor portale la pacienţii cu ciroză hepatică - Google Patents

Utilizarea propionatului de 3-(2, 2, 2-trimetilhidraziniu) dihidrat pentru tratamentul gastropatiilor portale la pacienţii cu ciroză hepatică Download PDF

Info

Publication number: MD4316C1
Authority: MD; Moldova
Prior art keywords: patients; liver cirrhosis; trimethylhydrazinium; gastropathies; portal
Prior art date: 2013-09-12

Application number

MDA20130063A

Other languages

English (en)

Romanian (ro)

Russian (ru)

Other versions

MD4316B1 (mo

Inventor

Георге АНГЕЛИЧ

Олег КРУДУ

Ульвия МАММАДОВА

Галина ПАВЛЮК

Original Assignee

Георге АНГЕЛИЧ

Олег КРУДУ

Ульвия МАММАДОВА

Галина ПАВЛЮК

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-09-12

Filing date

2013-09-12

Publication date

2015-08-31

2013-09-12 Application filed by Георге АНГЕЛИЧ, Олег КРУДУ, Ульвия МАММАДОВА, Галина ПАВЛЮК filed Critical Георге АНГЕЛИЧ

2013-09-12 Priority to MDA20130063A priority Critical patent/MD4316C1/ro

2015-01-31 Publication of MD4316B1 publication Critical patent/MD4316B1/mo

2015-08-31 Publication of MD4316C1 publication Critical patent/MD4316C1/ro

Links

208000019425 cirrhosis of liver Diseases 0.000 title claims abstract description 15
208000012895 Gastric disease Diseases 0.000 title claims abstract description 10
JFWLFLLRLZSBRA-UHFFFAOYSA-N 3-[(trimethylazaniumyl)amino]propanoate;dihydrate Chemical compound O.O.C[N+](C)(C)NCCC([O-])=O JFWLFLLRLZSBRA-UHFFFAOYSA-N 0.000 title claims abstract description 5
208000018556 stomach disease Diseases 0.000 claims description 5
239000003814 drug Substances 0.000 abstract description 2
238000002360 preparation method Methods 0.000 description 9
230000002496 gastric effect Effects 0.000 description 4
230000003902 lesion Effects 0.000 description 4
208000000624 Esophageal and Gastric Varices Diseases 0.000 description 3
208000025865 Ulcer Diseases 0.000 description 3
210000001156 gastric mucosa Anatomy 0.000 description 3
230000004089 microcirculation Effects 0.000 description 3
210000004877 mucosa Anatomy 0.000 description 3
230000000926 neurological effect Effects 0.000 description 3
230000008929 regeneration Effects 0.000 description 3
238000011069 regeneration method Methods 0.000 description 3
GZSOSUNBTXMUFQ-NJGQXECBSA-N 5,7,3'-Trihydroxy-4'-methoxyflavone 7-O-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 GZSOSUNBTXMUFQ-NJGQXECBSA-N 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
206010056091 Varices oesophageal Diseases 0.000 description 2
230000000767 anti-ulcer Effects 0.000 description 2
GZSOSUNBTXMUFQ-YFAPSIMESA-N diosmin Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 GZSOSUNBTXMUFQ-YFAPSIMESA-N 0.000 description 2
229960004352 diosmin Drugs 0.000 description 2
IGBKNLGEMMEWKD-UHFFFAOYSA-N diosmin Natural products COc1ccc(cc1)C2=C(O)C(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 IGBKNLGEMMEWKD-UHFFFAOYSA-N 0.000 description 2
230000000694 effects Effects 0.000 description 2
208000024170 esophageal varices Diseases 0.000 description 2
201000010120 esophageal varix Diseases 0.000 description 2
208000007386 hepatic encephalopathy Diseases 0.000 description 2
VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
201000002282 venous insufficiency Diseases 0.000 description 2
SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
206010000087 Abdominal pain upper Diseases 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
208000032274 Encephalopathy Diseases 0.000 description 1
206010053155 Epigastric discomfort Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
206010017788 Gastric haemorrhage Diseases 0.000 description 1
108010017480 Hemosiderin Proteins 0.000 description 1
229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 1
108010083204 Proton Pumps Proteins 0.000 description 1
208000012886 Vertigo Diseases 0.000 description 1
206010000059 abdominal discomfort Diseases 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
210000000013 bile duct Anatomy 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000004856 capillary permeability Effects 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
229960001596 famotidine Drugs 0.000 description 1
XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
206010016766 flatulence Diseases 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000003908 liver function Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000009854 mucosal lesion Effects 0.000 description 1
229960000381 omeprazole Drugs 0.000 description 1
230000035699 permeability Effects 0.000 description 1
208000007232 portal hypertension Diseases 0.000 description 1
210000003240 portal vein Anatomy 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
231100000889 vertigo Toxicity 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

MDA20130063A 2013-09-12 2013-09-12 Utilizarea propionatului de 3-(2, 2, 2-trimetilhidraziniu) dihidrat pentru tratamentul gastropatiilor portale la pacienţii cu ciroză hepatică MD4316C1 (ro)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
MDA20130063A MD4316C1 (ro)	2013-09-12	2013-09-12	Utilizarea propionatului de 3-(2, 2, 2-trimetilhidraziniu) dihidrat pentru tratamentul gastropatiilor portale la pacienţii cu ciroză hepatică

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
MDA20130063A MD4316C1 (ro)	2013-09-12	2013-09-12	Utilizarea propionatului de 3-(2, 2, 2-trimetilhidraziniu) dihidrat pentru tratamentul gastropatiilor portale la pacienţii cu ciroză hepatică

Publications (2)

Publication Number	Publication Date
MD4316B1 MD4316B1 (mo)	2015-01-31
MD4316C1 true MD4316C1 (ro)	2015-08-31

Family

ID=52440945

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MDA20130063A MD4316C1 (ro)	2013-09-12	2013-09-12	Utilizarea propionatului de 3-(2, 2, 2-trimetilhidraziniu) dihidrat pentru tratamentul gastropatiilor portale la pacienţii cu ciroză hepatică

Country Status (1)

Country	Link
MD (1)	MD4316C1 (mo)

2013
- 2013-09-12 MD MDA20130063A patent/MD4316C1/ro not_active IP Right Cessation

Also Published As

Publication number	Publication date
MD4316B1 (mo)	2015-01-31

Similar Documents

Publication	Publication Date	Title
Kasai et al.	1978	Technique and results of operative management of biliary atresia
Sikiric et al.	2023	Stable gastric pentadecapeptide BPC 157: Prompt particular activation of collateral pathways
Carter et al.	1958	Direct nonsuture coronary artery anastomosis in the dog
MD4316C1 (ro)	2015-08-31	Utilizarea propionatului de 3-(2, 2, 2-trimetilhidraziniu) dihidrat pentru tratamentul gastropatiilor portale la pacienţii cu ciroză hepatică
de Franchis, R. Bañares, C. Silvain	1998	Emergency endoscopy strategies for improved outcomes
Som et al.	1947	New approach to the treatment of esophageal varices
KR102733066B1 (ko)	2024-11-21	어류의 정액 또는 정소로부터 분리된 dna 단편 혼합물을 포함하는 허혈성 장염의 예방 또는 치료용 조성물
Döhler et al.	2008	Vasopressin analogues in the treatment of hepatorenal syndrome and gastrointestinal haemorrhage
MD4231C1 (ro)	2014-01-31	Remediu medicamentos pe bază de troxerutin şi carbazocrom pentru tratamentul gastropatiilor portale în ciroza hepatică
JP2009536193A (ja)	2009-10-08	予防若しくは治療の形態で投与されるα−ＭＳＨを用いた、改善の余地のある多様な病理学的過程に関する治療におけるニコチン、そのアナログ、その前駆体またはその誘導体の使用
Vannas et al.	1959	Hypophysectomy as a therapeutical method for proliferative diabetic retinopathy
Gaber	2022	Diseases of Lymphatics
RU2765920C1 (ru)	2022-02-04	Способ лечения острого геморроя с использованием лазерной геморроидектомии
Gomez et al.	1973	Repair of two false aneurysms of the abdominal aorta
RU2314100C1 (ru)	2008-01-10	Способ коррекции ишемического поражения кишечника при острой кишечной непроходимости
Learmonth	1947	The Problems of Portal Hypertension: Post-Graduate Lecture delivered at The Royal College of Surgeons of England on 10th October, 1947
MD4317C1 (ro)	2015-08-31	Utilizarea propionatului de 3-(2, 2, 2-trimetilhidraziniu) dihidrat pentru tratamentul pacienţilor cu ciroză hepatică avansată asociată cu insuficienţă cardiacă
US20240050470A1 (en)	2024-02-15	Method for Inhibiting Reperfusion Injury
RU2467752C2 (ru)	2012-11-27	Способ комплексного лечения острой тромбоэмболии легочной артерии
Bancroft et al.	1938	The treatment of actinomycosis with thymol
SU955942A1 (ru)	1982-09-07	Способ лечени артериальной гипертонии
Fočo et al.	2013	Vascular anomalies of the maxillofacial region: Diagnosis and management
RU2616988C1 (ru)	2017-04-19	Способ шунтирования желудка
Gonzalez-Suarez et al.	2003	Endoscopic treatment with Argon plasma coagulation for portal hypertensive gastropathy with no response to pharmacological therapy
CN116510023A (zh)	2023-08-01	一种化学品在制备预防和/或治疗慢性创面的产品中的用途

Legal Events

Date	Code	Title
2015-07-31	FG4A	Patent for invention issued
2016-04-30	KA4A	Patent for invention lapsed due to non-payment of fees (with right of restoration)
2017-03-31	MM4A	Patent for invention definitely lapsed due to non-payment of fees